An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
NCT03801278 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-12-13
Summary
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
Conditions
- Recurrent Bladder Cancer
Interventions
- DRUG
-
FPA144
Bemarituzumab administration every two weeks
Sponsors & Collaborators
-
Five Prime Therapeutics, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
NCT02278978 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.
NCT03718741 ·Status: TERMINATED ·Phase: NA
-
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
NCT05687721 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NCT04701918 ·Status: COMPLETED ·Phase: PHASE2
-
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
NCT02647112 ·Status: COMPLETED ·Phase: NA
-
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
NCT02901548 ·Status: TERMINATED ·Phase: PHASE2
-
Adjuvant Radiation for High Risk Bladder Cancer
NCT01954173 ·Status: TERMINATED ·Phase: NA
-
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
NCT07053735 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
NCT05052372 ·Status: TERMINATED
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
NCT03617913 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582 ·Status: RECRUITING ·Phase: PHASE2
-
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
NCT04018053 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT07122414 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
NCT03374488 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614 ·Status: RECRUITING ·Phase: PHASE2
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NCT05943379 ·Status: RECRUITING ·Phase: PHASE2
-
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
NCT03167151 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00191711 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
NCT02232646 ·Status: WITHDRAWN ·Phase: PHASE2